What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

UCLB launches funding for early-stage social ventures

UCLB, part of UCL Innovation & Enterprise, launches its search for early-stage social ventures to benefit from Proof of Concept funding.

Read More
Featured Technology—

Quadruplex-binding compounds – a novel anticancer strategy

We have a first-in-class optimized small-molecule drug candidate ready for IND enabling studies with superior efficacy and activity against pancreatic cancer compared to existing agents, together with a distinct mechanism of action.

Read more
Spotlight—

How does Portico Ventures support non-patentable and fast-to-deploy technologies?

The following interview took place in April 2019 towards the end of the one-year pilot phase of Portico Ventures. Following positive feedback from the Department of Computer Science where the pilot ran, Portico Ventures is now rolling out more widely across the university. Visit our newsroom to find out more.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

Development of new treatment for severe hemophilia A on track

/ UCLB News
BioMarin today announced it has submitted a marketing application to the European Medicines Agency (EMA), for the investigational gene therapy, ...

UCLB launches funding for early-stage social ventures

/ Social Ventures, UCLB News
UCLB, part of UCL Innovation & Enterprise, launches its search for early-stage social ventures to benefit from Proof of Concept ...

Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

/ Spinout News
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment ...

New commercialisation models to help bring more UCL discoveries to market

/ UCLB News
The launch of Portico Ventures sees the introduction of two new models for intellectual property (IP) commercialisation to support UCL ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Commercialising technology since 1993

0
Active spinouts
0
Active licences in 2018
0
Drug discoveries
0
New patent applications